Is Corcept Therapeutics Incorporated (CORT) at an inflection point?

Core Insights - Polen Capital's fourth-quarter investor letter for the Polen 5Perspectives Small Growth Strategy reported a return of -1.3% gross and -1.5% net of fees, underperforming the Russell 2000 Growth Index which returned 1.2% [1] - The small-cap asset class gained attention due to declining interest rates and improving earnings growth, with a notable focus on biotech as a major performer during the quarter [1] - The strategy's name was changed to emphasize the significance of the 5 viewpoints framework in investing [1] Company Focus: Corcept Therapeutics Incorporated - Corcept Therapeutics Incorporated (NASDAQ:CORT) is highlighted as a biopharmaceutical company developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders [2][3] - As of February 23, 2026, Corcept's stock closed at $35.34 per share, with a one-month return of -22.56% and a 52-week loss of 42.82% [2] - Corcept has a market capitalization of $3.724 billion [2] - The company is at an inflection point, expanding beyond its core indication with promising Phase 3 data for relacorilant in adrenal cancer and other indications, despite facing pressure from slower Korlym sales growth and uncertainty around pipeline approvals [3]